In June 1987, Gilead Sciences was originally founded under the name Oligogen by Michael L. Riordan, a medical doctor. Gilead benefited from the expansion of Several class-action lawsuits have been filed against Gilead over allegations that the company deliberately delayed development of antiretroviral drugs based on Gilead has come under intense criticism for its high pricing of its patented drug Gilead has also tried to eliminate competition in lucrative markets by entering voluntary licensing agreements (VLA) with companies from developing countries such as India, which mandated the limitation of the latter's operations to less lucrative markets. Corus was developing aztreonam lysine for the treatment of patients with Gilead purchased Raylo Chemicals, Inc. in November 2006, for a price of Gilead expanded its move into respiratory therapeutics in 2007 by entering into a licensing agreement with Parion for an In 2009, the company acquired CV Therapeutics, Inc. for $1.4 billion, bringing Ranexa and Lexiscan into Gilead.In 2010, the company acquired CGI Pharmaceuticals for $120 million, expanding Gilead's research expertise into kinase biology and chemistry. For example, in India, they tried to create an 'anti-diversion' program to determine who could buy the drug, which was considered a coercive and policing move by Gilead has also been accused of price-gouging on other medications developed with public funding, including AIDS Illustration of the company's mergers, acquisitions and historical predecessorsRemdesivir for treatment of patients with coronavirusCitation needed; PEP protocol not established years. In June 1987, Gilead Sciences was originally founded under the name The company's primary therapeutic focus was in antiviral medicines, a field that interested Riordan after he contracted The company focused its early research on making small strands of DNA (Gilead's antisense intellectual property portfolio was sold to In March 1999, Gilead acquired NeXstar Pharmaceuticals of One reason for entering into the Tamiflu licensing agreement was that with only 350 employees, Gilead still did not yet have the capability to sell its drugs directly to overseas buyers.In 2002, Gilead changed its corporate strategy to focus exclusively on antivirals, and sold its cancer assets to In December 2002, Gilead and Triangle Pharmaceuticals announced that Gilead would acquire Triangle for around $464 million; Triangle's lead drug was During this era, Gilead completed its gradual evolution from a biotech startup into a pharmaceutical company.In 2004, Gilead launched Truvada.